These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17631590)

  • 41. [New results of endocrine therapy of breast cancer (the role of Aromasin)].
    Semiglazov VF; Semiglazov VV; Klemtsel' AA; Barash NIu; Zhil'tsova EK; Bozhok AA; Mel'nikova OA; Paltuev RM; Dashian GA; Petrovskiĭ SG; Ivanov VG; Tonuzov EE; Berstein LM
    Vopr Onkol; 2004; 50(6):729-36. PubMed ID: 15755074
    [No Abstract]   [Full Text] [Related]  

  • 42. uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.
    Duffy MJ; McGowan PM; Harbeck N; Thomssen C; Schmitt M
    Breast Cancer Res; 2014 Aug; 16(4):428. PubMed ID: 25677449
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nonhormonal systemic therapy for advanced breast cancer: do the math!
    Bedard PL; Piccart-Gebhart MJ
    J Natl Cancer Inst; 2008 Dec; 100(24):1745-7. PubMed ID: 19066269
    [No Abstract]   [Full Text] [Related]  

  • 44. Optimal regimen for treatment-naive hormone receptor-positive HER-2 negative metastatic breast cancer.
    Bilgin B; Şendur MA; Hızal M; Akıncı MB; Dede DŞ; Yalçın B
    Future Oncol; 2019 Jan; 15(2):105-107. PubMed ID: 30484708
    [No Abstract]   [Full Text] [Related]  

  • 45. HER2-positive breast cancer, intrinsic subtypes, and tailoring therapy.
    Ellis MJ
    J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25139535
    [No Abstract]   [Full Text] [Related]  

  • 46. Targeting Breast Cancer Stem Cells to Overcome Treatment Resistance.
    Palomeras S; Ruiz-Martínez S; Puig T
    Molecules; 2018 Aug; 23(9):. PubMed ID: 30200262
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Indications for neoadjuvant chemotherapy for breast cancer.
    Bear HD
    Semin Oncol; 1998 Apr; 25(2 Suppl 3):3-12. PubMed ID: 9566201
    [No Abstract]   [Full Text] [Related]  

  • 48. New directions in improving response to endocrine therapy cancer.
    Mayer IS
    Clin Adv Hematol Oncol; 2016 Feb; 14(2):87-9. PubMed ID: 27057806
    [No Abstract]   [Full Text] [Related]  

  • 49. Emerging drugs in metastatic breast cancer: an update.
    Arslan C; Altundag K; Dizdar O
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):647-67. PubMed ID: 22122529
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Re: potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer.
    Kane RC
    J Natl Cancer Inst; 2012 May; 104(9):717-8; author reply 718. PubMed ID: 22472306
    [No Abstract]   [Full Text] [Related]  

  • 51. Hexamethylmelamine use in the treatment of metastatic breast cancer.
    Henderson IC; Shapiro CL
    Cancer Treat Rev; 1991 Mar; 18 Suppl A():91-8. PubMed ID: 1904313
    [No Abstract]   [Full Text] [Related]  

  • 52. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
    Mallmann P
    Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
    [No Abstract]   [Full Text] [Related]  

  • 53. Clinical usefulness and relevance of intermediate endpoints for cytotoxic neoadjuvant therapy.
    Fontanella C; Loibl S; von Minckwitz G
    Breast; 2015 Nov; 24 Suppl 2():S84-7. PubMed ID: 26279131
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Herceptin produces clinical benefit in metastatic breast cancer regardless of tumor response.
    Oncology (Williston Park); 2004 Aug; 18(9):1201. PubMed ID: 15471203
    [No Abstract]   [Full Text] [Related]  

  • 55. Predictive factors for response to chemotherapy in advanced breast cancer.
    Sjöström J
    Acta Oncol; 2002; 41(4):334-45. PubMed ID: 12234024
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predictive and Prognostic Value of the TauProtein in Breast Cancer.
    Bonneau C; Gurard-Levin ZA; Andre F; Pusztai L; Rouzier R
    Anticancer Res; 2015 Oct; 35(10):5179-84. PubMed ID: 26408675
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adjuvant therapy in node-negative breast cancer. A panel discussion.
    McGuire WL; Abeloff MD; Fisher B; Glick JH; Henderson IC; Osborne CK
    Breast Cancer Res Treat; 1989 Mar; 13(2):97-115. PubMed ID: 2659105
    [No Abstract]   [Full Text] [Related]  

  • 58. Chemotherapy for metastatic breast cancer.
    Mayer EL; Burstein HJ
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):257-72. PubMed ID: 17512448
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Window of Opportunity trials for biomarker discovery in breast cancer.
    Arnedos M; Roulleaux Dugage M; Perez-Garcia J; Cortes J
    Curr Opin Oncol; 2019 Nov; 31(6):486-492. PubMed ID: 31464762
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pertuzumab: a new anti-HER2 drug in the management of women with breast cancer.
    Dawood S; Sirohi B
    Future Oncol; 2015; 11(6):923-31. PubMed ID: 25760974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.